Retroviral Vector Biosafety: Lessons from Sheep by Van den Broeke, Anne & Burny, Arsène
© 2003 Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology • 2003:1 (2003) 9–12 • PII. S1110724303209128 • http://jbb.hindawi.com
COMMENTARY
Retroviral Vector Biosafety: Lessons from Sheep
Anne Van den Broeke∗ and Ars` ene Burny
Laboratory of Experimental Hematology, Bordet Institute, 1000 Brussels, Belgium
Received 6 June 2002; accepted 19 July 2002
The safety of retroviral-based systems and the possible transmission of replication-competent virus to patients is a major concern
associatedwithusingretroviralvectorsforgenetherapy.Whilemucheﬀorthasbeenputintothedesignofsaferetroviralproduction
methods and eﬀective in vitro monitoring assays, there is little data evaluating the risks resulting from retroviral vector instability
at post-transduction stages especially following in vivo gene delivery. Here, we brieﬂy describe and discuss our observations in an
in vivo experimental model based on the inoculation of retroviral vector-transduced tumor cells in sheep. Our data indicates that
the in vivo generation of mosaic viruses is a dynamic process and that virus variants, generated by retroviral vector-mediated re-
combination, may be stored and persist in infected individuals prior to selection at the level of replication. Recombination may
not only restore essential viral functions or provide selective advantages in a changing environment but also reestablish or enhance
the pathogenic potential of the particular virus undergoing recombination. These observations in sheep break new ground in our
understanding of how retroviral vectors may have an impact on the course of a preestablished disease or reactivate dormant or en-
dogenous viruses. The in vivo aspects of vector stability raise important biosafety issues for the future development of safe retroviral
vector-based gene therapy.
Vectors derived from retroviruses are the most exten-
sively used vehicles for gene transfer (reviewed by Hu and
Pathak [1]). In this respect, retroviral vectors display a
number of unique features including the absence of vi-
ral gene expression and the capacity to integrate into the
host genome, a prerequisite for permanent gene trans-
fer in a number of applications. The safety of retroviral-
based systems, however, and the possible transmission of
replication-competentvirustopatientsisamajorconcern
associated with using retroviral vectors for gene therapy.
It is well documented that retroviruses display high
recombination and mutation rates [2, 3]. Replication-
competent viruses (RCR) can be generated through re-
combination between the vector and either the helper
constructs required for vector production or endogenous
retroviruses present in the host genome. Both the host
cell derived RNA polymerase II and the virus-encoded
reverse transcriptase are incapable of exerting exonucle-
olytic proofreading activity and therefore contribute to
the generation of genetically divergent retroviruses. The
dimeric nature of the genome moreover allows template
switching of reverse transcriptase during the copying of
copackaged RNA molecules, leading to the generation of
recombinant proviruses harboring information derived
from both parental RNAs. For further information re-
garding the basic concepts of recombination, examples of
recombinational reassortment and their impact on retro-
virus evolution, we refer the reader to the reviews of Ne-
groni and Buc [4] and Mikkelsen and Pedersen [5].
Becauseofthesesafetyconcerns,screeningassayshave
been elaborated for testing the presence of RCR during
production of retroviral vectors, in ex vivo-transduced
cells and during patient follow-up [6, 7]. Much eﬀort has
been put into the design of safe retroviral vector produc-
tion methods for generating helper free recombinant vec-
tors through the development of systems with reduced
homology between retroviral vector and packaging com-
ponents, self-inactivating vectors, or split-genome con-
ditional packaging systems [8, 9, 10]. Cell culture stud-
ies have provided examples of retroviral genetic changes
introduced by recombination and there is extensive data
demonstratingtheimpactofrecombinationduringvector
preparation [5, 11, 12, 13]. However, in vitro approaches
currently used to monitor structural changes introduced
in the integrated vector post-transduction are limited by
the absence of host-associated processes that govern ge-
netic changes and therefore do not fully mimic the com-
plex in vivo situation.
There is very little data evaluating the dynamics of
provirus structural modiﬁcations in vivo, and the risks
resulting from retroviral vector instability at post-trans-
duction stages are largely ignored, especially following in
vivo gene delivery. The generation of mosaic retroviruses
has been described in mice and primates [14, 15, 16], but
to our knowledge, there is poor direct evidence of in vivo
recombination that involves retroviral vector sequences
and either exogenous or endogenous retroviruses. Hu-
man endogenous retroviruses (HERVs) are the proviral
remnants of previous retroviral infections and make up
as much as 8% of the human genome [17]. Most impor-
tantly, some endogenous retroviruses are capable of inter-
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vectors, through diﬀerent mechanisms including recom-
bination and transactivation [18]. Endogenous retroele-
ments thus represent a signiﬁcant source of functional vi-
ral sequences, which may serve as donors in recombina-
tion. In addition, proteins-provided in trans by retroviral
vectors may lead to the spread of otherwise inactive en-
dogenous retroviruses. This phenomenon may challenge
the safe usage of retroviral vector-based gene vehicles.
Although recombination between MLV-derived vec-
tors and human endogenous retroviruses may thus po-
tentially happen, there are no examples of in vivo cross-
species recombination, probably because these events re-
quire coinfection by viruses which normally replicate in
distinct host organisms. This hypothesis was further sup-
ported by data from patients and co-workers, indicat-
ing that human retroviruses may be ineﬃciently recog-
nizedandpackagedbytheMLVassemblymachinery[19].
However, in contrast with previous studies, recent data
from our laboratory revealed unexpected in vivo inter-
actions between distinct retroviral structures. Hereafter,
we brieﬂy describe and discuss our observations in an in
vivo ovine model, providing evidence for in vivo recom-
bination between a gibbon ape leukemia virus (GaLV)-
pseudotyped MLV-derived retroviral vector and bovine
leukemia virus, a leukemogenic complex retrovirus that
infects cattle and sheep. The ovine in vivo experimental
approach described here relies on the possibility to easily
detect novel acquired biological properties resulting from
recombination, thus providing a unique tool for studying
the changes in integrated retroviral structures. Our obser-
vations address the biosafety issue associated with retro-
viral vector stability in vivo, a key parameter that may im-
pact the therapeutic potential of retroviral vector-based
gene therapy.
We have developed a retroviral vector-mediated gene
transfer strategy in a model that was initially established
for investigating bovine leukemia virus (BLV)-associated
leukemia in sheep. BLV is a complex retrovirus closely re-
lated to the HTLV family of human retroviruses and the
ovine leukemia model provides an excellent means for
studying aspects of human complex retrovirus-induced
diseases(reviewedin[20,21]).Inthishighlyreproducible
model of BLV-induced lymphoid tumors, viral infection
can be monitored after one week postinoculation, follow-
ing injection of either naked provirus or virus particles
produced in tissue culture.
The lack of viral expression in the ovine tumors has
made it diﬃcult to identify the discrete mechanisms by
which BLV can mediate leukemogenesis [22, 23]. Tax,
the transactivating transcriptional activator of viral ex-
pression, is believed to initiate early events in the multi-
step process leading to full malignancy, but its expression
is not required to maintain the transformed phenotype.
To gain insight into the mechanisms that govern virus
silencing in BLV-induced tumors, we have studied YR2
leukemic B cells that contain a single, monoclonally in-
tegrated, silent provirus, which cannot be reactivated by
either in vitro stimulation, or in vivo injection of the tu-
mor cells or the cloned proviral DNA in sheep. Sequence
analysis of the YR2 proviral tax gene identiﬁed two G to
A transitions responsible for E to K amino acid changes
at positions 228 and 303 of the Tax protein (309 aa) re-
sulting in a transactivation-deﬁcient phenotype. (GaLV)-
pseudotypedpLTaxSNretroviralvector-mediatedtransfer
of wild-type tax into YR2 cells [24] resulted in the pro-
duction of BLV transcripts characterized by the parental
mutations in tax, thus potentially leading to a defective
provirus. Injection of sheep with transduced cells was
then assayed to investigate the in vivo infectious poten-
tial of BLV particles induced by LTaxSN. YR2LTaxSN inoc-
ulation resulted in rapid seroconversion and lead to the
in vivo rescue of replication-competent proviruses with
unique chimeric tax genes, which arose from recombina-
tion between the transduced LTaxSN vector-derived wild-
type tax and the YR2-derived tax sequences [25].
We furthermore found that while BLV-speciﬁc anti-
body titers rose over time in the majority of these inocu-
lated animals, a limited number of sheep displayed weak
and transient antibody responses that were no longer de-
tectablethreemonthspostinoculation.Mostinterestingly,
one of those seronegative animals converted to high sero-
logical titers 18months postinoculation, indicating that
recombinant infectious proviruses generated by recombi-
nation with retroviral vector sequences may survive and
emerge long after the initial injection. Finally, recent ob-
servationsinaYR2LTaxSN-injectedleukemicsheeprevealed
that a unique chimeric Tax-mutated replication-deﬁcient
provirus was integrated in the malignant B cell clone
while recombinant functional provirus had been consis-
tently monitored over the aleukemic period (Van den
Broeke, unpublished observations, 2001). This observa-
tion strongly supports the hypothesis that switching oﬀ
expression of Tax, an essential contributor to the onco-
genic potential of BLV, is linked with the onset of acute
leukemia.
In terms of BLV-associated leukemogenesis, our data
provided clear evidence for the role of strategically-
located mutations in retrovirus tumor-associated silenc-
ing, stressing the relevance of viral immunosurveillance
escape mechanisms, and thus recombination, in the on-
set of the tumor. Most importantly, in terms of viral vec-
tor biosafety, our in vivo experimental approach based
on the inoculation of retroviral vector-transduced tumor
cells (YR2LTaxSN) in sheep raised important questions re-
garding the in vivo stability of retroviral vectors, provid-
ing clear evidence for the presence of chimeric proviruses,
as well as the long-term storage and subsequent selection
of recombinant retroviral genetic information. Of partic-
ular interest was the emergence, as monitored by the full
seroconversion, of a functional BLV provirus after an 18-
month period of seronegative carrier state in one of our
experimental sheep. This suggests that the in vivo gen-
eration of mosaic viruses is a dynamic process and that
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recombination, may be stored and persist in the infected
individual prior to selection at the level of replication. Fi-
nally, our ﬁndings suggest that there is a potential link
between the modiﬁcation of an integrated proviral struc-
ture and the emergence of pathology. In our model, retro-
viruses face changing selective forces favoring either in-
creased viral ﬁtness during the productive stage of the in-
fection, or virus silencing during the leukemic stage of
the BLV-associated disease. Thus, the system is actively
driving recombination, generating retroviruses with al-
tered functional capacities to fulﬁl the novel in vivo re-
quirements. Reactivation restores full virulence. Silencing
is likely to facilitate escape from immune responses and
leads to full-blown malignancy. To our knowledge, this is
the ﬁrst example of a direct deleterious in vivo eﬀect as-
sociatedwithvector-mediatedrecombination.Inthispar-
ticular case, the mechanism by which the immune system
targets and destroys developing malignancies, is evaded
by the pre-malignant cell by downregulating its intrinsic
immunogenicity through recombination-mediated virus
silencing.
These in vivo observations using a sheep model break
new ground in our understanding how retroviral vectors
may have an impact on the course of a preestablished
disease or reactivate dormant or endogenous viruses. Re-
combinationmaynotonlyrestoreessentialviralfunctions
or provide selective advantages in a changing environ-
ment but also re-establish or enhance the pathogenic po-
tential of the particular virus undergoing recombination,
such as the silencing-associated leukemogenicity studied
as a model in our project. Our study furthermore stresses
the limitations associated with retroviral vector-mediated
gene delivery using current vectors in a host popula-
tioninfectedwithretroviruses(HIV,HTLV-I)orgenomes
that harbor endogenous retroelements. Although the ex-
actmechanismsleadingtothegenerationofmosaicretro-
viruses remain uncertain, our observations in sheep il-
lustrate the largely ignored potential risks associated with
retroviral gene transfer in humans. Because of the enor-
mousselectivepressuresexertedinvivo,eventheoretically
rare events may pose a realistic safety concern. Further
advancement in retroviral vector-mediated gene therapy
and development of safe strategies for gene delivery must
deal with the risks of in vivo recombination, generation of
mosaicretroviruses,andlong-termstorageofviralgenetic
information. Future research will probably need to focus
more on the in vivo aspects of vector biosafety and stabil-
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